1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Fernando Fervenza: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab in Treatment of PGNMID and C3 GN Daratumumab - Membranoproliferative Glomerulonephritis | Phase 2 | Completed | Fernando Fervenza | 12 | 2017-09-07 | 2022-08-31 |
| Rituxan in Churg Strauss Syndrome With Renal Involvement Rituximab, Prednisone - Churg-Strauss Syndrome | Phase 2 | Terminated | Fernando Fervenza | 4 | 2007-06-01 | 2011-12-08 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1)
Prednisone (1) · Rituximab (1) · daratumumab (1)
United States (2)
Fernando C Fervenza, MD (1) · Fernando C. Fervenza, M.D., Ph.D. (1)
UL1RR024150 (1)